Twenty-Year Nationwide Trends in Statin Utilization and Expenditure in Denmark
The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
HomeCirculation: Cardiovascular Quality and OutcomesVol. 10, No. 7Twenty-Year Nationwide Trends in Statin Utilization and Expenditure in Denmark Free AccessResearch ArticlePDF/EPUBAboutView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissionsDownload Articles + Supplements ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toSupplementary MaterialsFree AccessResearch ArticlePDF/EPUBTwenty-Year Nationwide Trends in Statin Utilization and Expenditure in Denmark Martin Bødtker Mortensen, MD, PhD, Erling Falk, MD, DMSc and Morten Schmidt, MD, PhD Martin Bødtker MortensenMartin Bødtker Mortensen From the Department of Cardiology, Aarhus University Hospital, Denmark (M.B.M., E.F.); Department of Internal Medicine, Regional Hospital of Randers, Denmark (M.B.M., M.S.); and Department of Clinical Epidemiology, Aarhus University Hospital, Denmark (M.S.) , Erling FalkErling Falk From the Department of Cardiology, Aarhus University Hospital, Denmark (M.B.M., E.F.); Department of Internal Medicine, Regional Hospital of Randers, Denmark (M.B.M., M.S.); and Department of Clinical Epidemiology, Aarhus University Hospital, Denmark (M.S.) and Morten SchmidtMorten Schmidt From the Department of Cardiology, Aarhus University Hospital, Denmark (M.B.M., E.F.); Department of Internal Medicine, Regional Hospital of Randers, Denmark (M.B.M., M.S.); and Department of Clinical Epidemiology, Aarhus University Hospital, Denmark (M.S.) Originally published11 Jul 2017https://doi.org/10.1161/CIRCOUTCOMES.117.003811Circulation: Cardiovascular Quality and Outcomes. 2017;10:e003811IntroductionDuring the past 20 years, numerous large randomized controlled trials have documented the efficacy and safety of statin therapy for both primary and secondary preventions of atherosclerotic cardiovascular disease.1 Accordingly, statin therapy constitutes the cornerstone of pharmacological prevention of atherosclerotic cardiovascular disease in all major international cholesterol guidelines.2,3 Statins are among the top-selling medications in both Europe and the United States, and the market for statin therapy is expected to grow as the population continues to age. In recent years, most statins have become available in generic versions with potentially great implications for their overall use and the associated costs to the healthcare system. Such information could provide important insights for European policy makers on healthcare value and future potential for improving cost-effectiveness of statin use. However, few previous studies have investigated national trends in statin use and costs, and none in a European country endorsing the guidelines issued by the European Society of Cardiology. We, therefore, examined nationwide 20-year trends in statin utilization and expenditure in Denmark.Methods and ResultsSetting and Statistical AnalysisThis study utilized data from 1996 to 2015. All inhabitants of Denmark have free access to tax-paid healthcare. Statin sales in the primary healthcare sector comprise purchases of prescription drugs only. Over-the-counter sale of statin is not available in Denmark. Drugs prescribed by physicians at discharge from hospitals or at ambulatory visits are dispensed from community pharmacies and therefore part of the primary sector sales. We retrieved data on use of statins according to the Anatomical Therapeutic Chemical classification system from the publicly accessible MEDical STATistics (Medstat), as described previously.4,5 Medstat has provided aggregate statistics on drug usage from the Danish primary sector since 1996. Although the pharmacy sale data in Medstat is only provided in aggregated format, it is based on individual-level prescription fillings. The registration includes drug sale in defined daily doses (DDD), both total counts and sales per 1000 inhabitants. The DDD is a World Health Organization-defined statistical measure of drug consumption, representing the assumed average maintenance dose required by an adult when the drug is used for its main indication. Reporting data in DDD allows for direct comparison of trends in drug use, independent of varying prices and pack sizes. Importantly, each year Medstat updates all data (including data from previous years) according to the most recent World Health Organization-defined DDD for each drug, which allows for comparison of drug use over time. We also used Medstat to obtain information on overall and individual annual statin expenditures. The expenditures were adjusted for price inflation assuming an annual inflation rate of 1.88% (average annual inflation of the Consumer Price Index in Denmark from 1996 to 2015). Additional information on Methods is provided in the Data Supplement.Trends in Statin UtilizationFrom 1996 to 2015, the overall use of statin therapy increased 62-fold from 2.2 to 137.3 DDD per 1000 inhabitants (Figure [A]; Figure I and Table I in the Data Supplement). The increase in statin use was most pronoun
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2016 European Guidelines on cardiovascular disease prevention in clinical practice
Piepoli, M. F., Hoes, A. W., Agewall, S., Albus, C., Brotons, C., Catapano, A. L., Cooney, M.-T., Corrà, U., Cosyns, B., Deaton, C., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw106 · Cited by 6,457
Salami, J. A., Warraich, H., Valero-Elizondo, J., Spatz, E. S., Desai, N. R., Rana, J. S., Virani, S. S., Blankstein, R., Khera, A., Blaha, M. J., et al. (2017) · JAMA Cardiology · doi:10.1001/jamacardio.2016.4700 · Cited by 370
Cited by
Global epidemiology of dyslipidaemias
Pirillo, A., Casula, M., Olmastroni, E., Norata, G. D., & Catapano, A. L. (2021) · Nature Reviews Cardiology · doi:10.1038/s41569-021-00541-4 · Cited by 882
Inclisiran—Safety and Effectiveness of Small Interfering RNA in Inhibition of PCSK-9
Wołowiec, Ł., Osiak, J., Wołowiec, A., Wijata, A., Grześk, E., Kozakiewicz, M., Banach, J., Nowaczyk, A., Nowaczyk, J., & Grześk, G. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15020323 · Cited by 43
“Applying appropriate pharmacotherapy for dyslipidemia, encouraging public education, increasing the availability of lipid tests, spreading greater awareness of dyslipidemia complications as well as continuously updating and developing dyslipidemia guidelines are key issues that help improve the treatment of dyslipidem…”
Background
Metadata
- Authors
- Mortensen, M. B., Falk, E., & Schmidt, M.
- Venue
- Circulation: Cardiovascular Quality and Outcomes
- Published
- 2017-07
- Volume
- 10
- Issue
- 7
- ISSN
- 1941-7705 (ISSN-L)
- 1941-7713
- OpenAlex
- W2736201749
- Cited by
- 52
- References
- 2
- FWCI
- 3.28
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Twenty-Year Nationwide Trends in Statin Utilization and Expenditure in Denmark. https://app.cochat.ai/papers/10.1161/circoutcomes.117.003811
- The paper
- Mortensen, M. B., Falk, E., & Schmidt, M. (2017). Twenty-Year Nationwide Trends in Statin Utilization and Expenditure in Denmark. Circulation: Cardiovascular Quality and Outcomes. https://doi.org/10.1161/circoutcomes.117.003811
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.